The transcription factor NF-kB is required for lymphocyte activation and proliferation as well as the survival of certain lymphoma types 1, 2 . Antigen receptor stimulation assembles an NF-kB activating platform containing the scaffold protein CARMA1 (also called CARD11), the adaptor BCL10 and the paracaspase MALT1 (the CBM complex), linked to the inhibitor of NF-kB kinase complex [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , but signal transduction is not fully understood 1 . We conducted parallel screens involving a mass spectrometry analysis of CARMA1 binding partners and an RNA interference screen for growth inhibition of the CBM-dependent 'activated B-cell-like' (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) 12 .
Here we report that both screens identified casein kinase 1a (CK1a) as a bifunctional regulator of NF-kB. CK1a dynamically associates with the CBM complex on T-cell-receptor (TCR) engagement to participate in cytokine production and lymphocyte proliferation. However, CK1a kinase activity has a contrasting role by subsequently promoting the phosphorylation and inactivation of CARMA1. CK1a has thus a dual 'gating' function which first promotes and then terminates receptor-induced NF-kB. ABC DLBCL cells required CK1a for constitutive NF-kB activity, indicating that CK1a functions as a conditionally essential malignancy gene-a member of a new class of potential cancer therapeutic targets.
For a better understanding of signal regulation by the CBM complex, we performed a mass spectrometry proteomic screen after CARMA1 immunoprecipitation. Sixteen peptides covering 54% of the length of CK1a were isolated from an excised band ( Fig. 1a and Supplementary Fig. 1 ). CK1a belongs to the CK1 family of serine/ threonine protein kinases, which regulates developmental and homeostatic processes including the Wnt/b-catenin pathway and circadian rhythm 13 . Co-immunoprecipitations in HEK293T cells showed that haemagglutinin (HA)-tagged CK1a interacted with V5-CARMA1 (Fig. 1b) . CARMA1, BCL10 and MALT1 associated with CK1a after TCR stimulation in Jurkat T lymphocytes, and in BJAB B cells stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin ( Fig. 1c-e) . Notably, phosphorylated forms of BCL10 and ubiquitinated species of MALT1, modifications due to signalling 14 , associated with CK1a. Moreover, MALT1 and BCL10 precipitations revealed TCR-induced recruitment of CK1a concomitantly with inhibitor of NF-kB kinase (IKK)-b and phosphorylated IKK-b (p-IKK-b; Fig. 1d and data not shown). Also, cytosolic CK1a reorganized into punctate structures that co-localized with CD3 clusters on TCR activation (Fig. 1f) , suggesting an association with CBM components within membrane microdomains 2, 15 . In contrast to TCR agonists, tumour necrosis factor-a (TNF-a), which does not use the CBM, induced no interaction between CK1a and CBM substituents ( Supplementary Fig. 2 ). Finally, antibody depletion of CK1a from cell lysates removed nearly the entire active CBM complex ( Supplementary Fig. 3 ). Hence, CK1a is a new component selectively entering the active CBM complex after antigen receptor stimulation. CK1a harbours a short and unique carboxy-terminal portion attached to the conserved kinase domain 13 ( Fig. 1a) . Removing this region (D283-337) abolished CK1a binding to CARMA1 (Fig. 1g) . In addition, the human (residues 283-337) and mouse (283-325) CK1a C-terminal domains were sufficient, with Y292 and D293 as the key residues, for CARMA1 association ( Fig. 1h and Supplementary  Fig. 4a, b) . We also found that both the coiled-coil (CC) and linker regions (CCL) of CARMA1 together were critical for CK1a binding. (Fig. 1i and Supplementary Fig. 4c ).
The CBM complex is an obligate gateway from lymphocyte antigen receptors to NF-kB activation 1, 3, [8] [9] [10] [11] . To define the functional importance of CK1a, we first decreased its endogenous levels by RNA interference in primary human T cells. CK1a (also called CSNK1A1) silencing reduced TCR-induced interleukin-2 (IL-2) production as did silencing of messenger RNA for NF-kB p65 (RELA) and BCL10 (Fig. 2a) . This was accompanied by diminished IL-2 receptor (CD25) upregulation, and reduced proliferation (Fig. 2b) . In Jurkat cells, CK1a knockdown with small interfering RNAs (siRNAs) decreased the TCR induction of an NF-kB luciferase reporter as efficiently as a BCL10 siRNA (Fig. 2c) . Again, TNF-amediated NF-kB was unaffected, underscoring the selective involvement of CK1a in the TCR-NF-kB pathway. Accordingly, CK1a-silenced primary T cells and Jurkat cells also displayed diminished p65 NF-kB nuclear translocation after TCR, but not TNF-a, stimulation ( Supplementary Fig. 5a-c) . By contrast, NF-kB activation proceeded normally when levels of CK1d or CK1e were reduced ( Supplementary Fig. 6 ). Thus, among the CK1s, CK1a provides an essential, non-redundant function in regulating TCR-induced NF-kB activation.
To achieve a better knockdown, single Jurkat clones stably expressing a small hairpin RNA (shRNA) against CK1a were generated. As expected, NF-kB activation was markedly reduced on stimulation, as IkBa phosphorylation and degradation were inhibited (Fig. 2d-f ). Other early TCR signalling events, such as ERK1/2 phosphorylation, overall tyrosine phosphorylation, calcium mobilization and NF-AT activation occurred normally ( Fig. 2e and Supplementary Fig. 5d-f ). Of note, NF-kB activity was restored when CK1a-silenced cells were LETTERS rescued with ectopic mouse CK1a (mCK1a), but not with mCK1a mutants lacking CARMA1 binding ability, indicating that CK1a function requires association with CARMA1 ( Fig. 2d and Supplementary Fig. 7) . Hence, CK1a is selectively required for optimal physiological activation of NF-kB on TCR stimulation in normal lymphocytes.
Promptly following TCR ligation, protein kinase C (PKC)-h phosphorylates CARMA1 and unleashes its adaptor functions 16, 17 . CARMA1 then promotes IkBa phosphorylation by recruiting signalling molecules, including BCL10, MALT1 and IKK 17, 18 . Although IKK was phosphorylated after stimulation of CK1a-silenced cells, p-IKK-b was no longer recruited to the CBM complex (Fig. 2f, g ). This parallels previous observations in CARMA1-and BCL10-deficient cells 19 . Hence, the recruitment of p-IKK and consequent alterations of IkBa are defective without CK1a. Nonetheless, CK1a still associated with CARMA1 in PKC-h-or BCL10-silenced cells, or after treatment with the PKC inhibitor rottlerin, although BCL10/MALT1 recruitment to CK1a/CARMA1 and NF-kB activation were diminished ( Supplementary Fig. 8 ). Thus, CK1a associates with CARMA1 independently of PKC-h and BCL10, and does not require PKC-h-dependent modifications of CARMA1.
To investigate the role of CK1a enzyme activity, we generated kinase-dead CK1a by introducing point mutations in the ATPase domain (K46R, D136N, or D136A) 20, 21 . In CK1a-silenced Jurkat cells, mCK1a(D136N) markedly enhanced TCR-induced NF-kB activation, surpassing the response in cells reconstituted with wildtype CK1a (Fig. 3a) . Human K46R, D136N and D136A CK1a mutants gave similar results (Supplementary Fig. 9a ). Accordingly, IkBa phosphorylation and degradation was augmented in mCK1a(D136N) expressing cells compared with wild-type mCK1a (Fig. 3b) . The CK1a(D136N) synergistic effect was abolished in BCL10-silenced cells, or when mCK1a(D136N/D293A) was used ( Supplementary Fig. 9d, e) , suggesting that enhanced NF-kB activity requires BCL10 and binding to CARMA1. Thus, CK1a kinase activity has a negative role in TCR-induced NF-kB activation, in addition to the positive signalling role of CK1a in the CBM complex.
By analogy with IKK-b, which marks BCL10 for degradation by phosphorylation 22 , we inferred that CK1a might phosphorylate a substrate to downregulate the CBM complex. CARMA1, which binds CK1a, was an attractive candidate. We observed that wild-type CK1a, but not CK1a(D136N), retarded the electrophoretic migration of CARMA1 in a l-phosphatase-dependent manner, suggesting that CK1a phosphorylates it ( Fig. 3c and Supplementary Fig. 10 ). Because CARMA1 contains 142 potential phospho-acceptors, we used truncation mutants to identify CK1a phosphorylation sites. In HEK293T cells, CARMA1-CCL(104-660) existed as two species, and wild-type CK1a, but not CK1a(D136N), shifted essentially all the CARMA1-CCL to the slow-migrating, l-phosphatase-sensitive species (Fig. 3d and Supplementary Fig. 10a, b) . CARMA1-CCL(104-616) was the shortest CK1a-sensitive construct, as a mutant lacking residues 606-616 was not modified (Fig. 3e) . The substitution to alanine of serines S603, S607 and S608 showed that only S608A and S603A/608A (2SA) were insensitive to CK1a, suggesting that S608 might be the key CK1a phosphorylation site (Fig. 3f) . NF-kB enhancement was observed in CARMA1-deficient Jurkat cells 11 reconstituted with CARMA1(2SA) and CARMA1(S608A) (Fig. 3g and Supplementary Fig. 10c, d ). This evidence indicates that CK1a specifically phosphorylates CARMA1 at S608, which impairs its ability to activate NF-kB.
Using a doxycycline-inducible shRNA retroviral library, we conducted a systematic screen for essential survival genes for two molecularly and clinically distinct lymphoma types, ABC and GCB (germinal centre B-cell-like) DLBCL 12, 23, 24 . ABC, but not GCB, DLBCL cells rely on constitutive NF-kB activation for proliferation and survival 25 . Previously, this screen identified CARMA1, BCL10 and MALT1 as critical components for ABC DLBCL cell survival 12 . Additional screening uncovered two CK1a shRNAs that were selectively lethal for ABC DLBCL cell lines (Fig. 4a) . We cloned these CK1a shRNA sequences into a GFP-expressing retroviral vector 12 , and infected cell lines representing ABC DLBCL, GCB DLBCL and multiple myeloma. CK1a shRNA expression decreased the fraction of GFP-positive, shRNA-expressing cells over time in all four ABC DLBCL cell lines but not in GCB DLBCL or multiple myeloma cell lines, confirming that CK1a knockdown is specifically lethal to ABC DLBCL cells (Fig. 4b) .
To evaluate CK1a participation in the NF-kB pathway in ABC DLBCL, the OCI-Ly3 cell line harbouring an IKK activity reporter consisting of an IkBa-luciferase fusion protein was used 12 . If IKK is inactivated, there is less phosphorylation and degradation of the IkBa-luciferase fusion protein and luciferase activity rises. Induction of CK1a shRNA expression increased luciferase activity, as did shRNAs targeting IKK-b (also called IKBKB), CARMA1, MALT1 and BCL10, whereas control shRNAs targeting the Spi-B transcription factor (SPIB) and EGFP had no effect (Fig. 4c) . Consistently, CK1a knockdown decreased NF-kB in the nuclei of 
OCI-Ly3 cells and reduced IkBa phosphorylation in HBL1, U2932
and OCI-Ly3 cell lines ( Supplementary Fig. 11 ). Thus, CK1a is required for the IKK-NF-kB signalling pathway in ABC DLBCL cells. We also detected a strong binding of CK1a to MALT1 and ubiquitinated MALT1 in ABC DLBCL but not GCB DLBCL cell lines (Fig. 4d) . Some ABC DLBCLs harbour mutant forms of CARMA1 that constitutively activate NF-kB and generate cytoplasmic aggregates that co-localize with MALT1 and IKK 26 . Such CARMA1 aggregates also contain CK1a, further implicating CK1a in CBM complex activity in ABC DLBCL (Fig. 4e) . We next tested whether the lethality of an shRNA targeting the CK1a 39-untranslated region could be prevented by wild-type CK1a or CK1a(DC), which does not bind CARMA1. Wild-type CK1a, but not CK1a(DC), rescued two ABC DLBCL cell lines from CK1a shRNA toxicity (Fig. 4f) . In contrast, neither wild type nor CK1a(DC) rescued ABC DLBCL cells from CARMA1 shRNA toxicity. Thus, direct interaction of CK1a with CARMA1 is apparently required for ABC DLBCL cell survival.
Our results have shown CK1a to be an important bifunctional modulator of lymphocyte adaptive immune responses. Whereas CK1a associates with CARMA1 and positively conveys TCR-induced NF-kB, it also phosphorylates CARMA1, thereby dampening signalling. This provides a conceptual framework for CK1a as a signalling gate, using both positive and negative influences to control the flow of information leading to gene induction. The phosphorylation and inactivation of CARMA1 by CK1a is reminiscent of the GSK3b/ CK1a cooperation to promote b-catenin destruction 27 , and our preliminary data indicate that CK1a might contribute to CARMA1 degradation ( Supplementary Fig. 10 ). We also provide genetic, biochemical and functional evidence that CK1a is an essential participant in the aberrant NF-kB activity required for ABC DLBCL subtype survival. Similar to IKK-b 22 , the positive function of CK1a supplants its negative role, probably because of the constitutive upstream activation signals. Of note, CK1a was neither mutated nor amplified in ABC DLBCL cell lines (data not shown), indicating that this CK1a dependency resembles the 'non-oncogene addiction' phenomenon in which the cancer cell phenotype depends on specific cellular genes 28, 29 . These 'conditionally essential malignancy' genes may or may not be oncogenes or the initiator genes for cancer, but they are essential for the propagation of a specific transformed phenotype and therefore attractive therapeutic targets 28, 29 . Notably, CK1a is required for the survival of ABC DLBCL cells with either mutant or wild-type CARMA1, revealing it to be a conditionally essential malignancy gene. However, CK1a is a complex target for chemotherapy given its contrasting roles in signalling. 
METHODS SUMMARY
Cell culture and reagents. Jurkat E6.1, BJAB and HEK293T cells were purchased from ATCC. Peripheral blood T cells were isolated from normal healthy donors as previously described 30 . CARMA1-deficient JPM50.6 Jurkat cells were provided by X. Lin 11 . Lymphocytes were activated with anti-CD3 and anti-CD28 (BD Biosciences), or with PMA (Sigma) and ionomycin (Sigma), or TNF-a (R&D). siRNAs used (Invitrogen) were BCL10, 59-GCCACGAACAACCUC-UCCAGAUCAA-39; CK1a.2, 59-CCTAGCCTCGAAGACCTCTTCAATT-39; CK1a.3, 59-GGCAAGGGCTAAAGGCTGCAACAAA-39; PKCh, 59-AAAUGG-UGAUUUCACUUUCGGCCGG-39; p65, 59-GAGCACCAUCAACUAUGAUG-AGUUU-39. CARMA1-binding-partner screen by mass spectrometry. CARMA1 was immunoprecipitated from HEK293T cells overexpressing V5-tagged CARMA1. CARMA1-containing complexes were resolved on SDS-PAGE and stained with colloidal Coomassie blue (Invitrogen). Bands were excised, in-gel trypsin digested, and subjected to LC-MS/MS mass spectrometry analysis. shRNA library screen. A retroviral shRNA library was constructed in the modified pRSMX plasmid containing a doxycycline-inducible H1 promoter for shRNA expression and a random 60-mer 'bar-code' sequence. The association of each bar-code with an shRNA sequence in each library plasmid was determined by sequencing. Screening used engineered cells that express the bacterial tetracycline repressor (TETR) 12 . 500-1,000 individual shRNA plasmids were combined to generate retroviral pools, which were used to infect TETR-expressing lymphoma and multiple myeloma cell lines. Puromycin-selected, infected cells were induced with doxycycline for shRNA expression in half of the culture. Three weeks after shRNA induction, bar-code sequences were amplified from the genomic DNA of induced and uninduced cells, fluorescently labelled, and hybridized to bar-code microarrays to identify shRNA vectors that were relatively depleted from the induced population. The effective CK1a shRNA sequences identified from the screen are: CK1a 1, 59-GACTCTGCATTAACTCTATAA-39 and CK1a 2, 59-GAGCAAGCTCTATAAGATTCT-39.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
